ranimustine has been researched along with Myeloproliferative Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, M; Ogawa, Y | 1 |
| Imamura, M; Kunieda, Y; Kurosawa, M; Maeda, S; Miyazaki, T; Morioka, M; Okabe, M; Sakurada, K; Sukegawa, M | 1 |
| Fujiwara, Y; Hirota, Y; Kobayashi, M; Kobayashi, T; Mitomo, Y; Ohno, R; Shirakawa, S; Tanaka, I; Yamada, H; Yamamoto, M | 1 |
3 other study(ies) available for ranimustine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Non-infectious Panniculitis during Hydroxyurea Therapy in a Patient with Myeloproliferative Disease.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Drug Substitution; Female; Glucocorticoids; Humans; Hydroxyurea; Myeloproliferative Disorders; Nitrosourea Compounds; Panniculitis; Remission Induction; Treatment Outcome | 2016 |
[Therapeutic effect of ranimustine(MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myeloproliferative Disorders; Nitrosourea Compounds; Remission Induction | 1991 |
[Phase II study of a new nitrosourea derivative, MCNU, in tablet form. Takai Blood Cancer Study Group].
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Humans; Myeloproliferative Disorders; Nausea; Nitrosourea Compounds; Tablets; Vomiting | 1987 |